4 / 9
Page 12
Notes:
allied
academies
Journal of Gastroenterology and Digestive Diseases | Volume 3
May 25-26, 2018 | New York, USA
World Liver Conference 2018
L
ower gastrointestinal bleeding (LGIB) is an important cause
of morbidity and mortality in patients with cirrhosis. It
occurs in approximately 20% of all patients who present with
gastrointestinal bleeding (GIB) with cirrhosis. Gastrointestinal
diseases that cause LGIB in patients with cirrhosis include
specific vascular diseases, inflammatory diseases and bowel
ischemia. However, in patients with less severe cirrhosis and
advancing age, the causes are much like the general population
andmust also be considered. The incidence and severity of LGIB
in patients with cirrhosis depends upon the incidence of specific
gastrointestinal diseases, coagulopathy, co-morbid diseases
and polypharmacy. The evaluation and treatment of patients is
adjusted to the rate and severity of hemorrhage and the clinical
status of the patient and may be complicated by the presence
of visual, auditory and cognitive impairment due to hepatic
encephalopathy. Bleeding may be chronic and mild or severe
and life threatening, requiring endoscopic, radiologic or surgical
intervention and methods to reduce portal hypertension.
Speaker Biography
Maxwell Chait is a Fellow of several prestigious organizations, including the
American College of Physicians, American College of Gastroenterology, American
Gastroenterological Association and the American Society for Gastrointestinal
Endoscopy. He is a Gastroenterologist and Assistant Professor of Medicine Columbia
University College of Physicians and Surgeons in New York City. He has authored
numerous publications in reputed journals. He is the Editor-in-Chief of the
Journal of
Liver: Disease & Transplantation
and serves on the Editorial Board of the
World Journal
of Gastrointestinal Endoscopy
.
e:
mdgi77@aol.comMaxwell Chait
Columbia University College of Physicians and Surgeons, USA
Lower GI bleeding in patients with cirrhosis